Australian clinical trial finds vitamin D does not ward off colds, flu

An Australian randomised controlled trial of vitamin D supplements has found they do not protect most people from developing colds, flu and other acute respiratory infections

vitamin D
Representative image
ANI US
2 min read Last Updated : Jan 14 2021 | 8:24 AM IST

An Australian randomised controlled trial of vitamin D supplements, led by QIMR Berghofer Medical Research Institute has found they do not protect most people from developing colds, flu and other acute respiratory infections.

The trial, which is the largest of its kind to study the relationship between vitamin D and respiratory infection to date did show, however, that the supplements may shorten the length of infection slightly and help ease the severity of those illnesses.

The study results have been published this week in the scientific journal The Lancet Diabetes and Endocrinology.

The researchers analysed self-reported health data from 16,000 Australians aged between 60 and 84, who participated in the QIMR Berghofer Medical Research Institute-led D-Health Trial.

Lead researcher and head of QIMR Berghofer's Cancer Aetiology and Prevention group, Professor Rachel Neale, said participants who received vitamin D supplements reported they had cold and flu symptoms for slightly less time than participants who did not take the vitamin. They also had severe symptoms for less time and needed less medication to manage their symptoms.

Professor Neale said the trial results are timely as people around the globe try to understand how best to improve their immunity in the face of the Covid-19 pandemic.

"The D-Health Trial was completed before the Covid-19 pandemic began so does not provide specific answers about this. However, our findings about reduced length and severity of respiratory tract infection suggests there could be some benefit to the immune system of taking a vitamin D supplement, particularly in people who are deficient.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Vitamin DcoldFlu

First Published: Jan 14 2021 | 8:14 AM IST

Next Story